Market Cap 617.78B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.56
Forward PE 21.88
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 7,097,243
Avg Vol 8,353,986
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 15%
Beta 0.24
Analysts Strong Sell
Price Target $273.67

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
dewmoore
dewmoore Aug. 4 at 9:09 PM
$SLS Family Tree check... 👀 Tom Cavanaugh was just named EVP & Worldwide Chairman of Innovative Medicine at $JNJ Guess who sits on the Board of Directors at $SLS ??? Katherine Bach Kalin. Guess where they both spent years overlapping as high-level executives in global strategy and product development from 2012 to 2017? CELGENE Celgene: BOTH Tom and Katherine overlapped as senior executives in global strategy/product development (2012–2017). $JNJ : Katherine spent nearly a decade at J&J in leadership/business development (2002–2011). You really think these two haven't grabbed a coffee or drinks in the past few days to catch up? 😂☕️🍻 Connect the dots! https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html
0 · Reply
Gebinator
Gebinator Aug. 4 at 8:53 PM
$SLS And -- is $JNJ promoting key staff for good strategic reasons? https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html
0 · Reply
dewmoore
dewmoore Aug. 4 at 8:52 PM
$SLS Great to see a $JNJ Product Director showing respect to Dr. Stergiou and $SLS, but let’s not read too much into it. Product Directors manage brand lifecycles, not secret corporate buyouts under strict NDAs. It’s great validation, but if J&J actually had an active NDA in play, corporate legal wouldn't let anyone give public high-fives on social media or anywhere else including LinkedIn It’s fun to dream, but stay grounded for now.... from me to you I still say my top 3 buyout boys are : #1 $MRK #2 $JNJ #3 $LLY
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 8:19 PM
$SLS $JNJ🤐 Den yparchei típota na deite edó. 👇 ✌️🙏❤️‍🩹
0 · Reply
RarelyRight
RarelyRight Aug. 4 at 7:54 PM
$DFTX $JNJ $CMPS $ATAI JNJ has to buy one of these. Spravato is going to get destroyed by psychedelics.
1 · Reply
Johnmtnb2018
Johnmtnb2018 Aug. 4 at 7:47 PM
$SLS $JNJ Looks like JNJ is the winner !
2 · Reply
Mountainmannn
Mountainmannn Aug. 4 at 7:41 PM
$ABUS I'd love to see $JNJ come in here buy us for 11 billion in stock...
1 · Reply
OmarKingW
OmarKingW Aug. 4 at 6:43 PM
$IBRX $JNJ $MRK VERY BULLISH FOR LONG INVESTORS: Things still moving ahead cleanly. Growth continues with more than 50m revenue and the only thing that hurt the numbers is 230.4m (.22 per share) spending vs 92.6m (.09 per share)from prior year) NON Cash accounting charges. Street expected the loss to be .08-.09 per share. The explanation is very clear from the company to me n it’s a cost of rapid growth for the year activating convertible notes, warrants, and related derivative liabilities. The widening seems concerning but it’s not in reality because we did grow rapidly from $1.80 all the way to $12. THE STORY BEEING TOLD IS NOTHING CHANGES GROWTH AND EXPANSION CONTINUES RESULTING INTO SOME OF THE NON CASH SPIKE) THESE WILL BE MANGED GOING FORWARD AND WILL REDUSE SIGNIFICANTLY GOING FORWARD. THINK: LONG AND STRONG 💪🏼
0 · Reply
Diefreeandsell
Diefreeandsell Aug. 4 at 6:19 PM
$IBRX $JNJ $MRK VOLUME wow it's really great today. No catastrophe! 14.15mil shares, +14% compared to typical volume of 12.41mil by 2:09 pm ET. Typical daily volume is 19.4mil shares over the past 6 months. Co's commercial execution has significantly altered its financial risk profile over the past few quarters. It just reported its Q2 2026 financials, delivering $50.7 million in net product revenue from ANKTIVA in USA only. This is up 92% year-over-year and marks the eighth consecutive quarter of sequential revenue growth since launch, you're disappointed? WTF Bottom Line: The current $357M+ cash pile, paired with an ANKTIVA commercial run rate now exceeding $200 million annually, provides ImmunityBio with a stable runway through late 2027. Late 2027-WTF!!! This comfortably covers the company past its crucial January 6, 2027 PDUFA date and right up to the anticipated late-2026 BCG-naïve FDA submission window. You think it won't succeed, think again!
1 · Reply
H_hi
H_hi Aug. 4 at 5:31 PM
$NVO we need to merge with $JNJ asap!
0 · Reply
Latest News on JNJ
Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 1 day ago

Johnson & Johnson Transcript: Investor update


Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 2 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device


Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 5 days ago

Johnson & Johnson lowers 2026 profit forecast


Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 6 days ago

Explainer: Can J&J finally put the talc litigation behind it?


Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 7 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits


J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 7 days ago

J&J offers $5.5bn to settle baby powder lawsuits


DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 19 days ago

DePuy Synthes Acquires Expanding Innovations™


Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026


Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Slides: Q2 2026


Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Earnings release: Q2 2026


Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Quarterly report: Q2 2026


Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 20 days ago

Johnson & Johnson Hikes Guidance, Stock Falls


Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 20 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise


Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 20 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook


The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 26 days ago

The Big 3: UNH, KO, JNJ

KO UNH


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 2 months ago

Johnson & Johnson to buy Firefly Bio for $1 billion


dewmoore
dewmoore Aug. 4 at 9:09 PM
$SLS Family Tree check... 👀 Tom Cavanaugh was just named EVP & Worldwide Chairman of Innovative Medicine at $JNJ Guess who sits on the Board of Directors at $SLS ??? Katherine Bach Kalin. Guess where they both spent years overlapping as high-level executives in global strategy and product development from 2012 to 2017? CELGENE Celgene: BOTH Tom and Katherine overlapped as senior executives in global strategy/product development (2012–2017). $JNJ : Katherine spent nearly a decade at J&J in leadership/business development (2002–2011). You really think these two haven't grabbed a coffee or drinks in the past few days to catch up? 😂☕️🍻 Connect the dots! https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html
0 · Reply
Gebinator
Gebinator Aug. 4 at 8:53 PM
$SLS And -- is $JNJ promoting key staff for good strategic reasons? https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html
0 · Reply
dewmoore
dewmoore Aug. 4 at 8:52 PM
$SLS Great to see a $JNJ Product Director showing respect to Dr. Stergiou and $SLS, but let’s not read too much into it. Product Directors manage brand lifecycles, not secret corporate buyouts under strict NDAs. It’s great validation, but if J&J actually had an active NDA in play, corporate legal wouldn't let anyone give public high-fives on social media or anywhere else including LinkedIn It’s fun to dream, but stay grounded for now.... from me to you I still say my top 3 buyout boys are : #1 $MRK #2 $JNJ #3 $LLY
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 8:19 PM
$SLS $JNJ🤐 Den yparchei típota na deite edó. 👇 ✌️🙏❤️‍🩹
0 · Reply
RarelyRight
RarelyRight Aug. 4 at 7:54 PM
$DFTX $JNJ $CMPS $ATAI JNJ has to buy one of these. Spravato is going to get destroyed by psychedelics.
1 · Reply
Johnmtnb2018
Johnmtnb2018 Aug. 4 at 7:47 PM
$SLS $JNJ Looks like JNJ is the winner !
2 · Reply
Mountainmannn
Mountainmannn Aug. 4 at 7:41 PM
$ABUS I'd love to see $JNJ come in here buy us for 11 billion in stock...
1 · Reply
OmarKingW
OmarKingW Aug. 4 at 6:43 PM
$IBRX $JNJ $MRK VERY BULLISH FOR LONG INVESTORS: Things still moving ahead cleanly. Growth continues with more than 50m revenue and the only thing that hurt the numbers is 230.4m (.22 per share) spending vs 92.6m (.09 per share)from prior year) NON Cash accounting charges. Street expected the loss to be .08-.09 per share. The explanation is very clear from the company to me n it’s a cost of rapid growth for the year activating convertible notes, warrants, and related derivative liabilities. The widening seems concerning but it’s not in reality because we did grow rapidly from $1.80 all the way to $12. THE STORY BEEING TOLD IS NOTHING CHANGES GROWTH AND EXPANSION CONTINUES RESULTING INTO SOME OF THE NON CASH SPIKE) THESE WILL BE MANGED GOING FORWARD AND WILL REDUSE SIGNIFICANTLY GOING FORWARD. THINK: LONG AND STRONG 💪🏼
0 · Reply
Diefreeandsell
Diefreeandsell Aug. 4 at 6:19 PM
$IBRX $JNJ $MRK VOLUME wow it's really great today. No catastrophe! 14.15mil shares, +14% compared to typical volume of 12.41mil by 2:09 pm ET. Typical daily volume is 19.4mil shares over the past 6 months. Co's commercial execution has significantly altered its financial risk profile over the past few quarters. It just reported its Q2 2026 financials, delivering $50.7 million in net product revenue from ANKTIVA in USA only. This is up 92% year-over-year and marks the eighth consecutive quarter of sequential revenue growth since launch, you're disappointed? WTF Bottom Line: The current $357M+ cash pile, paired with an ANKTIVA commercial run rate now exceeding $200 million annually, provides ImmunityBio with a stable runway through late 2027. Late 2027-WTF!!! This comfortably covers the company past its crucial January 6, 2027 PDUFA date and right up to the anticipated late-2026 BCG-naïve FDA submission window. You think it won't succeed, think again!
1 · Reply
H_hi
H_hi Aug. 4 at 5:31 PM
$NVO we need to merge with $JNJ asap!
0 · Reply
LindaRitter799
LindaRitter799 Aug. 4 at 5:27 PM
$XLF $PLAY $JNJ $ABTC $NNDM XLF tracks major financial institutions, Dave & Buster's benefits from entertainment demand, Johnson & Johnson provides defensive healthcare exposure, American Battery Technology advances recycling, and Nano Dimension develops additive electronics.
1 · Reply
TheUnmaker
TheUnmaker Aug. 4 at 5:05 PM
$TNXP Looks bottomed to me. $PFE $JNJ $PG $SLS
2 · Reply
Diefreeandsell
Diefreeandsell Aug. 4 at 4:08 PM
$IBRX Most right but one big diff is that IBRX had better sales than $JNJ Inlexo and prob gained more mkt share to boot . It was lack of BCG from $MRK that kept uSA sales from being even higher. That's about to be remedied later this year and sales should improve dramatically in US and take off in SA and UAE. Oh and wait till BCP naïve indication gets approved!! Need more BCG!!
1 · Reply
CHARTBUSTER12
CHARTBUSTER12 Aug. 4 at 1:49 PM
$JNJ GOOD morning my friends JNJ one of my picks in 2026 for a move higher above 300 dollars. MY friends this a great run company and i do expect bigger things for JNJ this year . HAVE a blessed day
0 · Reply
focafoca99
focafoca99 Aug. 4 at 1:40 PM
$JNJ just announced EVP Jennifer Taubert will retire from Innovative Medicine effective Sept 1, 2026. https://www.rapidticker.com/news/jnj-sec-filing-8-k-5282b6
0 · Reply
Diefreeandsell
Diefreeandsell Aug. 4 at 1:10 PM
$IBRX you forgot to mention growing sales against competition from major commercial launch from $JNJ inlexo! Co grew market share despite that! Double digit growth for anktiva, 15% qtr over qtr shows gaining traction not eroding due to any competition from bp.
0 · Reply
Diefreeandsell
Diefreeandsell Aug. 4 at 11:54 AM
$IBRX This is actually great since looks like the core revenue stream recorded for Q2 2026 remains almost entirely U.S. . Sales grew and not impacted by competition from $JNJ. The rest of world sales will come next qtr, but USA sales are outstanding!
1 · Reply
BENNYST
BENNYST Aug. 4 at 10:22 AM
$SLS $JNJ $PFE evaluating a buyout, Dr. Stergiou must look beyond the money. Public optics and politics matter. Pfizer ($PFE) currently suffers from a terribly negative public image due to Fauci’s legal battles and his invocation of the Fifth Amendment, directly tied to Pfizer's COVID vaccines. Partnering with them is a brand disaster. Meanwhile, Johnson & Johnson ($JNJ) aligns perfectly with oncology maintenance, enjoys superior public standing, and fits Washington's wavelength (echoing Stergiou's Fox News ties). If a buyout happens, choosing J&J over Pfizer is a masterstroke. Choose J&J. 🚀 Bullish
6 · Reply
Dr_Yolo
Dr_Yolo Aug. 4 at 7:39 AM
0 · Reply
quezoitm
quezoitm Aug. 4 at 3:59 AM
$SLS What isn’t obvious is what a coup buying $SLS will be for whoever wins the bid. Buying the next evolution in cancer care that could target 20+ cancers, is non toxic, dramatically extends patients lives and quality of life will add 10% to the share price of a large pharmaceutical. If $JNJ pays $30B for $SLS but adds 10% to their $600B market cap they’ll be getting Sellas Life Sciences for free. They’ll get paid to buy the damn company! Print a hazard ratio below 0.5 and it’s gonna be a bidding war. That’s capitalism.
5 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 4 at 1:12 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
NEWBIGTECH
NEWBIGTECH Aug. 3 at 5:07 PM
$SLS SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Regal trial. 36.9% institutional ownership of $SLS WILL $JNJ $MRK $BMY start a bidding war?
0 · Reply